{"id":785914,"date":"2023-09-25T10:18:38","date_gmt":"2023-09-25T14:18:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/"},"modified":"2023-09-25T10:18:38","modified_gmt":"2023-09-25T14:18:38","slug":"editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/","title":{"rendered":"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., Sept.  25, 2023  (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company\u2019s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine\u2019s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company\u2019s current and future pipeline of products.<\/p>\n<p>\u201cAs we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren\u2019s caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into robust business strategy with disciplined portfolio prioritization and value creation. Additionally, she has led multiple successful US and global product launches. Caren\u2019s expertise and track record make her the ideal leader to help Editas reach this goal for patients,\u201d said Gilmore O\u2019Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.<\/p>\n<p>Ms. Deardorf added, \u201cWith a clear focus on bringing EDIT-301 into the market for people living with sickle cell disease, \u2018right now\u2019 is the optimal time for Editas to build a commercial team and strategy. I look forward to driving the business forward alongside this strong Leadership Team as we bring EDIT-301 \u2013 and future pipeline medicines \u2013 through the clinic to commercialization.\u201d<\/p>\n<p>Caren Deardorf brings to Editas more than 25 years of international biotechnology leadership across a range of companies and therapeutic areas. Most recently, Ms. Deardorf served as the Chief Commercial Officer of Magenta Therapeutics. Prior to Magenta, she served as the Chief Commercial Officer of Ohana Biosciences where she was responsible for developing a commercial strategy, including planning for the company\u2019s first product launch.<\/p>\n<p>Earlier in her career, Ms. Deardorf held a variety of commercial roles of increasing responsibility at Biogen, most recently serving as Vice President, Product Development &amp; Commercialization, leading and executing a highly successful global launch of SPINRAZA<sup>\u00ae<\/sup>, a treatment for children and adults with spinal muscular atrophy. During her tenure at Biogen, Ms. Deardorf was instrumental in building the multiple sclerosis (MS) franchise and helping to establish Biogen\u2019s global leadership through US and worldwide brand management, including leading the brand and launch strategy for TECFIDERA<sup>\u00ae<\/sup> and the successful US and EU launches of TYSABRI<sup>\u00ae<\/sup> and AVONEX<sup>\u00ae<\/sup>.<\/p>\n<p>Ms. Deardorf holds a Bachelor of Science degree in biology from Tufts University and a Master of Business Administration from the Olin Graduate School of Business at Babson College. Ms. Deardorf serves on the Boards of Directors for Crinetics Pharmaceuticals and for NeuroSense Therapeutics. She is also a board member for the Pan-Mass Challenge, a non-profit organization that raises funds for Dana-Farber Center Institute.<\/p>\n<p>\n        <strong>About<\/strong>\u00a0<strong>Editas Medicine<\/strong><br \/>As a clinical-stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR\/Cas12a and CRISPR\/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute\u2019s Cas12a patent estate and Broad Institute and Harvard University\u2019s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iuOVZJfTP-scYfGGIH2E5Yy-uVImnv-c8smsssxSqCqLe2OEqIRJyicYOlv8v7td8PHelNJw1dZW5GcgJTXVRgjzTh7Wu4NKepT_Knsh-iw=\" rel=\"nofollow noopener\" target=\"_blank\">www.editasmedicine.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials, and clinical development of the Company\u2019s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company\u2019s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption \u201cRisk Factors\u201d included in the Company\u2019s most recent Annual Report on Form 10-K, which is on file with the\u00a0Securities and Exchange Commission, as updated by the Company\u2019s subsequent filings with the\u00a0Securities and Exchange Commission, and in other filings that the Company may make with the\u00a0Securities and Exchange Commission\u00a0in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.<\/p>\n<p>A photo accompanying this announcement is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FXeHDQS1bw7VLCJw3xMAt1sQh0WpDEcsvwJgaR1LizY_eASJqTThv2ZZnIW35todnquypSVgn0htPp2PqEnIOSXhK3Xw4wUhy2KzFCbE4BFHcsfSFAanhSu2tOzvnWH0KA7hLKz7w4wutVNS1OjLs0DAvX0n1cCg0LTKCoXDVAAWw1iA0UI26o1U3qU5qkwM4CD6dr38oEepyqRNK9mdu-HEp3iWH7SrnzmsbwjN9s7wOMihxyqeSBelhOmMUJxlzYoT_ES11TfUpSy2yiF9rA==\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/www.globenewswire.com\/NewsRoom\/AttachmentNg\/1a4cdbf9-9748-4d22-95b6-c03e4665de73<\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTkxNjM2ODktNzcwMC00ZTQyLWE3ZjktMTMwODdmNDExMjYwLTEwMzc1OTk=\/tiny\/Editas-Medicine-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Media and Investor Contact:\r\nCristi Barnett\r\n(617) 401-0113\r\ncristi.barnett@editasmed.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company\u2019s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine\u2019s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company\u2019s current and future pipeline of products. \u201cAs we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren\u2019s caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into robust business strategy with disciplined portfolio prioritization and value creation. Additionally, she has led multiple successful US and global product &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-785914","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company\u2019s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine\u2019s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company\u2019s current and future pipeline of products. \u201cAs we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren\u2019s caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into robust business strategy with disciplined portfolio prioritization and value creation. Additionally, she has led multiple successful US and global product &hellip; Continue reading &quot;Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-25T14:18:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer\",\"datePublished\":\"2023-09-25T14:18:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/\"},\"wordCount\":887,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/\",\"name\":\"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=\",\"datePublished\":\"2023-09-25T14:18:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/","og_locale":"en_US","og_type":"article","og_title":"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) &#8212; Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company\u2019s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine\u2019s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company\u2019s current and future pipeline of products. \u201cAs we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren\u2019s caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into robust business strategy with disciplined portfolio prioritization and value creation. Additionally, she has led multiple successful US and global product &hellip; Continue reading \"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-25T14:18:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer","datePublished":"2023-09-25T14:18:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/"},"wordCount":887,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/","name":"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=","datePublished":"2023-09-25T14:18:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkyNzQ1NyM1ODI5NTgyIzIwMjYwMjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/editas-medicine-strengthens-executive-leadership-team-with-appointment-of-caren-deardorf-as-chief-commercial-and-strategy-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785914","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=785914"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/785914\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=785914"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=785914"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=785914"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}